Gut-Directed Hypnotherapy Success Rate: What the Research Actually Shows

This page walks through every response-rate figure that reputable GDH marketing tends to quote, names the study it came from, and explains why the numbers vary. Every percentage here is from published research on research populations. None of it is a response-rate claim about this practice’s own clients.

Before quoting any percentage, it is worth being precise about what the percentage actually measures. Gut-directed hypnotherapy research uses two distinct outcomes that get sloppily conflated in marketing copy: response and remission. They are not the same thing.

Response is defined in most GDH trials as a 50% or greater improvement on a validated IBS symptom severity instrument, most commonly the IBS Symptom Severity Score (IBS-SSS). The IBS-SSS ranges from 0 to 500 and measures abdominal pain frequency and severity, bloating severity, bowel habit satisfaction, and overall quality-of-life interference. A patient who enters a trial at 300 on the IBS-SSS and leaves at 150 is a responder, because their symptom burden has halved. Response does not mean the symptoms have disappeared — it means they have meaningfully dropped.

Remission is a different and stricter benchmark. It generally means an IBS-SSS score below 75, representing essentially resolved symptoms with minimal day-to-day interference. Remission rates in the research literature are always lower than response rates, because a patient can cross the 50% improvement threshold without reaching the remission threshold. When you see a “success rate” quoted for gut-directed hypnotherapy, it is almost always reporting response rather than remission.

A third definition that sometimes appears is global improvement on a 7-point Likert-type scale where patients rate themselves as “much better,” “somewhat better,” or similar. That is a patient-reported satisfaction measure rather than a standardised symptom score, and it tends to run slightly higher than IBS-SSS response. It is fine as a secondary outcome but should not be mistaken for the primary trial endpoint.

The practical consequence: when someone tells you “hypnotherapy has a 76% success rate,” what they almost always mean is “76% of patients in the Miller 2015 Manchester audit met the 50%+ IBS-SSS improvement threshold at end of treatment.” That is genuinely meaningful, but it is not the same as 76% of patients becoming symptom-free, and it is not the same as 76% of people who start any form of self-directed hypnotherapy improving.

The single most-cited gut-directed hypnotherapy success figure traces back to a retrospective audit published in Alimentary Pharmacology & Therapeutics: Miller V, Carruthers HR, Morris J, Hasan SS, Archbold S, Whorwell PJ. “Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients.” 2015;41(9):844-855. PMID 25736234.

This is worth sitting with. Miller and colleagues at the University Hospital of South Manchester reviewed 1,000 consecutive IBS patients treated on the Manchester Protocol over two decades. The patients were not cherry-picked for likelihood of response — they were the entire consecutive caseload referred for gut-directed hypnotherapy, which means the sample includes the refractory, medication-resistant, and previously-failed-every-other-treatment patients who made it to a tertiary IBS hypnotherapy service in the first place.

A few specifics from Miller 2015 that rarely make the marketing headlines but matter for interpretation:

• Protocol. 12 weekly sessions of clinician-delivered gut-directed hypnotherapy with daily home audio practice in between. Personalised within the Manchester framework rather than scripted delivery.
• Population. Refractory IBS — patients who had failed other first-line treatments before being referred for hypnotherapy. This is arguably a harder population than a general IBS sample, not easier.
• Measurement. Response defined using standardised symptom severity scoring at end of treatment. Not patient-report-only; not practitioner-impression.
• Non-responders. ~24% did not meet the response threshold. The paper discusses non-responder analysis — the other 24% is not hidden.
• Durability. Long-term follow-up data indicated benefits persisted in the majority of responders at 5-year follow-up without additional sessions.

Miller 2015 is the evidence anchor for virtually every subsequent discussion of gut-directed hypnotherapy effectiveness. Later trials have generally attempted to replicate it, shorten the protocol (Palsson 2006), or test whether the format can be modified (Hasan 2019 on telehealth, Peters 2023 on app delivery) without losing response. The 76% figure has held up surprisingly well as a reference point across those replications, particularly for completed-protocol clinician-delivered work.

Three reasons Miller 2015’s 76% has become the standard reference point rather than one of the smaller trial figures.

First, sample size. n=1,000 is an order of magnitude larger than most other GDH trials. Whorwell 1984 — the original Lancet paper that put gut-directed hypnotherapy on the map — had 30 patients. Palsson 2006 had under 100. Peters 2016 had 74. A 1,000-patient consecutive audit simply has more statistical weight, and reviewers and journalists tend to default to the largest defensible figure when they quote a field.

Second, protocol fidelity. Miller 2015 was conducted at the institution where the Manchester Protocol was developed, by the team that developed it. This is as close to “the protocol as intended” as the literature gets. When Palsson 2006 reported 71% on the condensed UNC variant, the slight difference was attributed partly to protocol differences rather than a challenge to the Miller finding.

Third, corroborating replications. The 76% figure has been approximately reproduced across several independent contexts. Hasan 2019 (PMID 30702396) compared face-to-face Manchester Protocol delivery to live Skype delivery in a randomised comparison and reported 76% response in the in-person arm, matching Miller 2015 almost exactly. Independent audits of the Manchester Protocol in other centres have reported figures in the same 70-76% range. A number that keeps showing up across methods and centres earns more weight than one that appears in a single trial.

None of this means 76% is what any specific individual will experience. It is a research-population figure from refractory IBS patients on a validated clinician-delivered protocol. Your personal odds are modulated by hypnotisability, severity, comorbidities, protocol adherence, and practitioner fit. The research gives you a base rate, not a prediction.

Here is the seven-study landscape that most serious GDH discussion draws from. Together, they make a reasonably coherent picture: clinician-delivered GDH clusters in the 65-76% response range; app-delivered GDH is a different format with different adherence characteristics.

Walking through them chronologically:

• Whorwell et al., 1984 (The Lancet). The original randomised controlled trial. 30 severely refractory IBS patients, randomised to gut-directed hypnotherapy or supportive psychotherapy. The hypnotherapy arm showed dramatic symptom improvement relative to controls. Small sample, but a landmark paper because it established that IBS symptoms responded to a psychological intervention in a way that did not fit the prevailing view of the condition as purely motility or peripheral.
• Gonsalkorale et al., 2003 (Gut). Long-term follow-up of patients treated on the Manchester Protocol. Demonstrated that the majority of initial responders maintained improvement years after the protocol ended, establishing that the durability pattern was not an artefact of brief trials.
• Palsson and colleagues, 2006 (UNC Protocol). Reported a 71% response rate on a condensed 7-session format developed at the University of North Carolina. Important because it demonstrated the Manchester-style approach could be compressed without catastrophic loss of response.
• Miller 2015 (PMID 25736234). 76%, n=1,000, the reference audit discussed above.
• Peters 2016 (PMID 27397586). A randomised trial directly comparing gut-directed hypnotherapy to the low-FODMAP diet. Both produced equivalent GI symptom improvement (around 70-72% response in both arms); GDH showed superior psychological outcomes (anxiety, depression, quality of life). This is the most cited modern head-to-head between the two major first-line IBS interventions.
• Hasan 2019 (PMID 30702396). Randomised comparison of face-to-face Manchester Protocol versus live Skype delivery. 76% response in-person vs 65% via telehealth — not statistically different. Live clinician presence (via video) retained most of the effect of being physically in the room.
• Peters 2023 (PMID 36661117). Retrospective evaluation of the Nerva app. 9% of 2,843 trial starters completed all 42 audio sessions; 64% of the 190 completers with outcome data (6.7% of starters) reported improvement. The authors disclose direct financial relationships with Mindset Health.

One of the most clinically useful findings in the GDH literature came from Hasan 2019 (PMID 30702396), the Manchester group’s own randomised comparison of face-to-face delivery against live Skype delivery of the same 12-session protocol. The 76% in-person response matched the Miller 2015 audit almost exactly. The telehealth arm reported 65% response — 11 percentage points lower, but not statistically significantly different given the sample size.

This finding is load-bearing for two practical reasons. First, it means that clinician-delivered gut-directed hypnotherapy does not require in-person attendance to retain most of its clinical effect — a huge win for patients in regions without local specialist availability (which is most of Canada). Second, it isolates what is doing the work: the load-bearing variable is live clinician presence, not the room. The clinician is adjusting pacing, noticing resistance, adapting metaphor, and managing the relationship in real time; whether that happens in person or via video appears to matter less than whether it happens at all.

This is also the bridge between the clinician literature and the app literature. Going from in-person clinician to live-video clinician preserves most of the effect (Hasan 2019: 76% → 65%, not significantly different). Going from live-video clinician to pre-recorded audio with no clinician removes the live adjustment mechanism entirely — and that is where the adherence pattern in Peters 2023 appears. It is not that audio hypnotherapy is useless; it is that the absence of a live responder changes who completes the protocol.

The single most important paper for understanding app-based GDH success is Peters SL, Gibson PR, Halmos EP. “Smartphone app-delivered gut-directed hypnotherapy improves symptoms of self-reported irritable bowel syndrome: A retrospective evaluation.” Neurogastroenterology & Motility. 2023;35(4):e14533. PMID 36661117.

The paper looked at 2,843 users who started a Nerva free trial. Of those, 1,428 (50%) purchased the app. Only 253 (9%) completed all 42 sessions. End-of-program outcome data was available for just 190 completers — 6.7% of starters. Among those 190 measured completers, 64% reported significant symptom improvement. The authors — who disclose being paid consultants and shareholders in Mindset Health, the manufacturer — themselves conclude that “adherence to app-delivered gut-directed hypnotherapy was low” and that “a controlled trial comparing face-to-face to app-delivered GDH is indicated.”

Those numbers are not a condemnation of the app — for the 9% who finish, the 64% improvement rate among measured completers is consistent with the underlying Manchester Protocol’s response profile. They are a realism check. The denominator matters. A 64% response rate among 6.7% of starters is not the same thing as a 64% response rate among people who buy the app, and it is not at all the same thing as the 76% response rate on clinician-delivered protocols where the denominator is completers of a protocol whose completion is actively supported.

A second, more recent analysis by Simicich and colleagues (2024, available as PMC11179457) looked at Nerva users independently and reported that 31.7% of paid users reached end-of-program surveys and completed an average of 18.22 out of 42 sessions — about 43% of the intended protocol exposure. That is higher than Peters 2023’s 9% full-completion figure, but still well below the exposure level the Manchester Protocol was validated on.

One of the most distinctive features of the gut-directed hypnotherapy evidence base is the durability of response. Unlike IBS-specific medications — which generally produce symptom control while being taken and see symptoms return on discontinuation — GDH response tends to persist after treatment ends, often for years, without additional sessions.

Miller 2015 reported that the majority of responders maintained clinically meaningful improvement at 5-year follow-up with no further hypnotherapy sessions. Gonsalkorale 2003 reported directionally similar long-term maintenance in an earlier long-term follow-up study on Manchester Protocol patients. Taken together, these two data points suggest that gut-directed hypnotherapy is producing something closer to a persistent retraining effect on the gut-brain axis than a temporary symptom masker that requires ongoing dosing.

That said, durability is not universal. A minority of responders report partial regression of symptoms over time, particularly during significant life stress (major illness, bereavement, major work or family transitions). Occasional maintenance sessions are a reasonable option in those situations. The overall pattern — drop during protocol, flat maintenance for years — is a real advantage of the modality relative to medication, and it is one of the main reasons cost-per-response analyses tend to favour gut-directed hypnotherapy over long horizons.

Predicting individual response from published research is imperfect, but several factors reproducibly correlate with better or worse outcomes in GDH trials. These are probabilistic predictors, not deterministic ones — individuals outside the classic responder profile still respond, and individuals inside it sometimes do not.

The reproducible predictors across the GDH literature:

• Hypnotisability. Measured on standardised scales like the Stanford Hypnotic Susceptibility Scale or Tellegen Absorption Scale. Patients scoring in the medium-to-high range respond at higher rates. Roughly 70% of the population is in the responsive range; the remaining 30% includes both low hypnotisables and highly analytic, control-oriented cognitive styles that resist hypnotic induction.
• Symptom severity. Mild-to-moderate IBS tends to respond slightly better than the most severe presentations, though Miller 2015’s refractory population still hit 76%. Severity is not disqualifying — it just widens response variability.
• Comorbid anxiety, depression, or trauma. Untreated, these can interfere with relaxation-based protocols. Treated (or treated in parallel), they do not preclude response — and GDH often improves the psychological comorbidity alongside the GI symptoms (Peters 2016 specifically showed this).
• Treatment adherence. Daily home practice between sessions is predictive. Patients who skip home audio consistently tend to show blunted response. This is one of the most addressable variables.
• Clinician-patient fit. Less easily quantified, but present in the literature as a moderator — particularly for patients with trauma history or significant health anxiety where the therapeutic relationship does real work.

A response rate of 76% means 24% of patients do not meet the response threshold even after completing the full protocol. That is a non-trivial fraction of patients, and any honest discussion of GDH success rate has to acknowledge who those patients are and what should happen next.

The main non-responder categories identified in the research literature:

• Low hypnotisability. A subset of the population scores below the responsive range on standardised hypnotisability scales. For this group, any hypnosis-based intervention is likely to be muted regardless of clinician skill or protocol choice. Estimated at roughly 10-15% of the general adult population.
• Missed structural or systemic drivers. Some patients presenting as “IBS” turn out to have inflammatory bowel disease, small intestinal bacterial overgrowth, bile acid malabsorption, pelvic floor dyssynergia, celiac disease, or other conditions requiring targeted medical intervention. GDH is unlikely to resolve symptoms driven primarily by untreated organic disease.
• Untreated comorbid mental health issues. Severe untreated depression, major anxiety disorders, active PTSD, or trauma histories can interfere with the relaxation and imagery work of GDH. Addressing the mental health comorbidity in parallel often unlocks response; attempting GDH alone without addressing the comorbidity frequently does not.
• Adherence failure. Patients who attend sessions but do not engage in daily home practice show substantially blunted response rates. The home practice is where much of the gut-brain retraining actually happens between sessions.
• Practitioner-patient mismatch. The therapeutic relationship is a real active ingredient in any psychological intervention. Non-response to one practitioner does not reliably predict non-response to a different one.

For patients who complete the full Manchester or UNC Protocol without meeting the response threshold, the research-supported next steps include: a careful review of the initial GI workup to exclude missed organic disease; a registered-dietitian-led low-FODMAP trial (Peters 2016 showed equivalent GI outcomes); CBT-for-IBS (comparable evidence base, different mechanism); pelvic floor physiotherapy if dyssynergia is suspected; and a measured trial of IBS-specific pharmacotherapy. The non-responder category is not a dead end — it is a fork, and each branch has its own evidence base.

It is important to be direct about where the GDH evidence base is strong and where it is genuinely softer. The 65-76% response band is not pulled out of thin air, but the underlying research has real constraints that honest readers should understand.

The genuine limitations:

• Smaller trial sizes (with Miller 2015 as an outlier). Most GDH trials have fewer than 100 patients. Miller 2015’s n=1,000 audit is the exception; the underlying RCT literature is built on smaller samples that are more sensitive to statistical noise.
• Self-selected samples. Patients who enrol in GDH trials are, by definition, patients open to a psychological intervention for a GI condition. That selection alone may produce higher response than would appear in an unfiltered IBS population randomly assigned to hypnotherapy against their preference.
• Observer-blinded placebo controls are hard to design. You cannot meaningfully “blind” a patient to whether they received 12 sessions of hypnotherapy or not. Trials typically use an active control (like supportive psychotherapy in Whorwell 1984) rather than an inert placebo. The evidence is stronger on “is GDH better than nothing” than on the precise magnitude of the specific hypnotic mechanism.
• Centre effects. A large portion of the flagship evidence comes from one centre (University Hospital of South Manchester) and a handful of closely-related groups. Independent replication at arm’s length is more limited than it could be.
• Non-responder characterisation is thin. We know roughly 24% do not respond, but the literature has less detail on systematic non-responder profiling than it could. This is one of the most valuable open research questions in the field.
• Real-world delivery variability. Published trial response rates reflect delivery by clinicians trained specifically in the Manchester or UNC Protocol, with strong adherence support. Response rates in clinics that follow the protocol loosely, or where the clinician is inexperienced, may be materially different — but there is not systematic data on this because clinics do not typically publish their outcomes.
• A 2014 Cochrane systematic review concluded that hypnotherapy is promising for IBS but called for larger, better-controlled trials. That call has been partially answered by subsequent work (Miller 2015, Peters 2016, Hasan 2019), but it remains fair to say the evidence base would be stronger with more large, independent, centre-diverse replications.

None of these limitations changes the central conclusion: gut-directed hypnotherapy is one of the best-evidenced psychological interventions for IBS, and the 65-76% response band for clinician-delivered protocols is a defensible summary of the literature. The limitations matter for reading any single claim with appropriate uncertainty — not for dismissing the modality.